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Virally regulated HIV-1 particles were expressed from DNA plasmids encoding Gag, protease, reverse transcriptase, Vpu, Tat, Rev, and Env. The
sequences for integrase, Vpr, Vif, Nef, and the long terminal repeats (LTRs) were deleted. Mutations were engineered into the VLP genome to
produce particles deficient in activities associated with viral reverse transcriptase, RNase H, and RNA packaging. Each plasmid efficiently secreted
particles from primate cells in vitro and particles were purified from the supernatants and used as immunogens. Mice (BALB/c) were vaccinated
intranasally (day 1 and weeks 3 and 6) with purified VLPs and the elicited immunity was compared to particles without Env (Gagp55), to soluble
monomeric Envgp120, or to soluble trimerized Envgp140. Only mice vaccinated with VLPs had robust anti-Env cellular immunity. In contrast, all mice
had high titer anti-Env serum antibody (IgG). However, VLP-vaccinated mice had antisera that detected a broader number of linear Env peptides, had
anti-Env mucosal IgA and IgG, as well as higher titers of serum neutralizing antibodies. VLPs elicited high titer antibodies that recognized linear
regions in V4-C5 and the ectodomain of gp41, but did not recognize V3. These lentiviral VLPs are effective mucosal immunogens that elicit broader
immunity against Env determinants in both the systemic and mucosal immune compartments than soluble forms of Env.
© 2006 Elsevier Inc. All rights reserved.Keywords: HIV; VLP; Env; Mucosal vaccination; VaccineIntroduction
The ultimate goal of an AIDS vaccine is to elicit potent
cellular and humoral immune responses that will result in
enduring, broadly protective immunity (reviewed in Slobod et
al., 2005; Spearman, 2003). While much effort has focused on
elucidating the mechanisms and specificity of cellular immune
responses, less is known about virus-specific antibody
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doi:10.1016/j.virol.2006.08.032responses mediate viral control during the primary infection and
maintain the viral set point in chronic infection (Hamer, 2004).
However, administration of human monoclonal antibodies
passively protects against virus exposure in the HIV-1/
chimpanzee (Conley et al., 1996; Murthy et al., 1998), SIV/
monkey (Gardner et al., 1995; Haigwood et al., 1996) and
SHIV/monkey models (Foresman et al., 1998; Li et al., 1997;
Mascola et al., 1999, 2000; Shibata et al., 1999), demonstrating
the ability of antibody alone to mediate protection against
pathogenic virus infection. Thus, one goal of an AIDS vaccine
should be to elicit robust and broadly reactive cellular and
humoral immunity in both systemic and mucosal immune
compartments, thereby maximizing the potential for protection
from variant HIV-1 strains by different routes of exposure.
A particle-based immunogen, such as a non-infectious virus-
like particle (VLP), is a promising candidate for a safe and
effective AIDS vaccine. VLPs are defined as self-assembling,
non-replicating, non-pathogenic, and preferably genomeless
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infectious virions. There are multiple combinations of viral
proteins that may be used to generate VLPs, however, they must
contain Gag gene products in order to assemble and bud from
cells. Envgp160 may also be processed and incorporated as
trimeric spikes protruding from the surface of these particles.
The VLP used in this study is expressed from a virally
regulated, multi-gene DNA plasmid. However, unlike many
other VLPs currently being tested in AIDS vaccine research, our
VLP-DNA plasmids can express multiple viral gene products
from the same cell intracellularly and secrete these VLPs
extracellularly from primate cells from a single DNA plasmid in
vivo (Young and Ross, 2005; Young et al., 2004).
Other multi-gene-based VLP expression systems have been
developed to express VLPs from DNA plasmids (Ellenberger et
al., 2004, 2005; Smith et al., 2004; Hammonds et al., 2003).
While these approaches successfully elicited cellular immunity
against VLP antigens, these VLPs elicited limited binding
antibody and little, if any, neutralizing antibodies, even after
multiple vaccinations (Amara et al., 2001; Ellenberger et al.,
2004, 2005; Smith et al., 2004; Wyatt et al., 2004). In addition,
low to undetectable cellular or humoral immune responses were
observed at mucosal sites. The lack of a robust antibody
responses may be due, in part, to the in vivo production of
particles that were primarily retained intracellularly and
therefore these viral antigens were processed for MHC class I
presentation. Lastly, the lack of neutralizing antibodies in these
studies may be a result of (1) the elicitation of low antibody
titers or (2) the specific envelope chosen for incorporation into
these particles.
Over the past 20 years, multiple AIDS vaccine strategies
have been developed, but each has failed to protect against
disease (for reviews, see Egan, 2004; Haigwood, 2004; Sauter
et al., 2005; Slobod et al., 2005; Spearman, 2003). Early trials
using monomeric HIV-1 envelopes, while eliciting high titer
antibodies, failed to elicit antibodies capable of neutralizing
HIV-1 in vitro. However, the role of Env appears critical for the
induction of protective immunity in recent AIDS vaccines
(Amara et al., 2002; Letvin et al., 2004), which may point to
other antibody and cellular immune mechanisms, such as
antibody-dependent cytotoxicity (ADCC) (Forthal et al., 2001;
Forthal et al., 1999; Gomez-Roman et al., 2005; Peng et al.,
2005), as important mediators of protection. Inclusion of Env in
a multi-component AIDS vaccine results in lower viral set
points and higher CD4 counts following challenge compared to
the same vaccines lacking Env (Amara et al., 2002; Letvin et al.,
2004).
Envelope on the native virion is predicted to form a trimer
(Farzan et al., 1998; Kwong et al., 1998; Wyatt et al., 1998).
Thus, while neutralizing antibody responses appear to be an
important component to elicit in an AIDS vaccine, they tend to
recognize highly conformational epitopes on Env that may not
be immunogenic in vivo. The inability of monomeric envelopes
to elicit neutralizing antibodies is most likely due to differences
in structure between monomeric forms of gp120 and oligomeric
forms of envelope as they are expressed on the surface of a virus
particle. Several vaccine strategies have incorporated anoligomeric/trimeric form of Env in order to elicit cross-reactive
immunity that neutralizes viral infection (Beddows et al., 2005;
Bower et al., 2004, 2005; Pancera et al., 2005; Pancera and
Wyatt, 2005; Sanders et al., 2002; Yang et al., 2000, 2002). The
expression of trimeric Env on the surface of a particle does
appear to elicit higher titers of neutralizing antibodies than
soluble gp120 following intramuscular injection (Hammonds et
al., 2005), even though much of the neutralizing antibodies
were directed at membrane embedded cellular proteins.
To overcome this problem, soluble trimers of Env have been
developed. Soluble, stabilized Env trimers are hypothesized to
mimic the trimeric structure of the envelope on the native virion
and possibly induce conformationally dependent antibodies that
recognize epitopes present only on native virion-associated
envelopes. Several of these trimeric Env immunogens do elicit
slightly higher titers of neutralizing antibodies than monomeric
Envgp120 (Barnett et al., 2001; Bower et al., 2004; VanCott et al.,
1997; Yang et al., 2001). Often, these oligomeric Env proteins
are produced by eliminating the natural cleavage site recognized
by cellular proteases (Chakrabarti et al., 2005; Srivastava et al.,
2002; Yang et al., 2002; Zhang et al., 2001). The lack of elicited
high titer, broadly reactive neutralizing antibodies by these
immunogens is associated with the elicitation of primarily non-
neutralizing antibodies (Pancera et al., 2005; Schulke et al.,
2002; Si et al., 2003), because these uncleaved envelopes are in
non-native forms or are processed through different cellular
pathways than cleaved forms of Env (Adams and Scheid, 2001;
McCune et al., 1988; Pancera et al., 2005; Pancera and Wyatt,
2005). Therefore, in this study, mice were vaccinated with
soluble envelopes (monomeric Envgp120 or trimeric Envgp140) or
trimeric envelopes that were membrane retained on an HIV-1
VLP to determine if the form(s) and presentation of envelope to
the immune system influence the elicited immunity.
Results
In vitro expression and particle purification of virus-like
particles
An HIV-1 virus-like particle expressing plasmid was
constructed from a proviral genome, as previously described
(Young et al., 2004). The full-length HIV-1 VLP genome
expressed Gag, protease (PR), reverse transcriptase (RT), Vpu,
Tat, Rev, and Env gene products to produce a PR-processed, but
immature particle. A second VLP was expressed from a Gag
only codon-optimized sequence that produced an unprocessed,
immature particle. Plasmids expressing monomeric Envgp120 or
trimeric Envgp140 envelopes have been previously described
(Bower et al., 2004).
Expression of VLPs was determined in vitro following
transient transfection of primate (COS) cells with each DNA
plasmid. Cell culture supernatants and lysates containing Gag
gene products were detected following SDS-PAGE andWestern
blot (Young et al., 2004). Particles were purified from the
supernatants of transiently transfected cells by ultracentrifuga-
tion (20–60% sucrose gradient), and collected fractions were




89.6 ADA YU-2 CAANb PVO.4 THROc MuLV
HIV VLP 80 d 160 80 40 40 40 10
gp140 80 10 10 10 10 10 10
gp120 80 10 10 10 10 10 10
a Antisera from vaccinated mice was incubated with each virus pseudotyped
with the indicated viral envelopes.
b CAAN=CAAN5342.A2.
c THRO=THRO4156.18.
d IC50 on sera collected at week 10. Inhibition of viral infection of TZM-bl
cells was assessed by the additional reduction in infectivity beyond the
background of sera from age-matched naïve mice.
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as previously described for wild-type virions (Fig. 1) (Chertova
et al., 2002; Dettenhofer and Yu, 1999; Mouland et al., 2000;
Tang et al., 2003; Wang et al., 1998).
Cell-mediated immunity elicited by VLPs
Mice (BALB/c) were vaccinated intranasally with (1)
purified HIV-1 VLPs, (2) Gagp55 only particles, (3) purified
soluble trimerized Envgp140, or (4) soluble monomeric
Envgp120, at day 1 and weeks 3 and 6. Collected splenocytes
were stimulated in vitro with peptides specific for HIV-1 Gag,
Pol or Env (Table 1). Mice vaccinated with the HIV-1 VLPs
had a robust cell-mediated immune response against Gag, Pol
and Env. Four pools of Env peptides were used to detect
splenocyte responses (mINF-γ) specifically against the C1
region, the V3 region, a pool representing the gp120 region of
Group M consensus Env, or a pool representing the gp41
region of Group M consensus Env. Mice vaccinated with
soluble Envs had a reduced cellular response, as measured by
mINF-γ production, compared to mice vaccinated with HIV
VLPs (Fig. 2). Cellular responses against Gag elicited by HIV
VLPs were statistically similar to the responses elicited by
Gag only particles. Age-matched mice, as well as splenocytes
from mice vaccinated with VLPs and stimulated with an
irrelevant peptide or unstimulated, had few mINF-γ secreting
splenocytes (0–7 spots) following in vitro re-stimulation (data
not shown).
VLP-bound envelope efficiently elicits anti-Env antibody
All mice vaccinated with HIV VLPs or soluble envelopes
had anti-Env antibodies against gp120 following the firstFig. 1. Virus-like particle production by sucrose density gradient ultracentrifu-
gation. Supernatants from COS cells transiently transfected with HIV VLP
expressing DNA were concentrated through a 20% glycerol cushion and then
subjected to 20–60% (w/v) sucrose density gradient-equilibrium gradient
ultracentrifugation. Fractions were collected from top to bottom, precipitated
with 10% TCA, and proteins were detected by Western blot analysis. (A) HIV
VLP. (B) Gag only VLP. Percent of each sucrose fraction lane 1, 20%; lane 2,
24%; lane 3, 28%; lane 4, 32%; lane 5, 36%; lane 6, 40%; lane 7, 44%; lane 8,
48%; lane 9, 52%. All samples were electrophoresed through a 10%
polyacrylamide/SDS gel and transferred to a PVDF membrane or silver stained.
Proteins were immunoblotted with HIV-1 Ig (1:10000) and mouse anti-human
IgG (1:10000) and visualized by enhanced chemiluminescence. Arrows indicate
bands of HIV-1 antigens.inoculation, which increased after each subsequent vaccination.
Mice vaccinated with soluble envelopes were administered a
10- to 100-fold higher dose of envelope than mice vaccinated
with membrane-bound envelope on the surface of the VLPs
(Fig. 3A). However, even though the amount of Env on the VLP
was similar to the 1 μg dose of soluble envelope, the VLPs
elicited a log higher titer of anti-Env antibodies (Fig. 3B). Mice
vaccinated with VLPs had higher IgG2a titers compared to IgG1,
indicating a T helper type 1 immune response. In contrast, mice
vaccinated with soluble Envgp140 or Envgp120 elicited a
predominately IgG1 antibodies, indicating a predominately T
helper 2 response.
Both anti-Env IgG and IgAwere detected in mice vaccinated
with VLPs (Fig. 4). The highest titers were detected in the lungs,Fig. 2. Elicitation of interferon-γ producing splenocytes. ELISpots were
performed on isolated splenocytes from vaccinated mice collected at week 8.
Cells (1×106) were stimulated independently with peptides representing four
different regions of Env: (a) the first constant region of gp120 (C1), (b) the V3
loop region of Env (V3), (c) the entire gp120 region (gp120), or (d) the entire
gp41 region (gp41). Peptides in the gp120 and gp41 peptide pools were 15mers
overlapping by 11 amino acids. The C1 and V3 pools are described in the
Materials and methods. Splenocytes were also stimulated independently with
pools of peptides representing Gag or Pol regions. Following stimulation, cells
were assayed for mINF-γ. Nef peptides were used as a non-specific negative
control. Splenocytes stimulated with PMA/ionomycin had colonies too
numerous to count.
Fig. 3. Anti-Env serum antibodies. (A) Total serum anti-gp120 Env IgG. Serum
samples were collected prior to immunization (week 0) and 2 weeks after each
vaccination (weeks 2, 5, and 8). Each symbol represents the average endpoint
anti-Env serum antibody titer (n=6). (B) Symbols represent each individual
mouse anti-Env serum IgG endpoint titer. The line represents the average titers
plus the standard deviation (SD) (week 8). The statistical significance of the
difference between groups was calculated by the Student's t test.
Fig. 4. Total anti-Env IgG and IgA in the mucosa. Anti-gp120 Env antibody
titers were determined in three mucosal tissues (lungs, intestines, and vagina) at
week 8 post-vaccination from HIVVLP- or gp140 (10 μg)-vaccinated mice. (A).
IgG. (B) IgA. Each bar represents the average anti-Env antibody titer (n=6). The
statistical significance of the difference between groups was calculated by the
Student's t test.
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the vagina and intestine, albeit at lower titers (Fig. 4). Mice
vaccinated with soluble envelopes (10 μg) generally had
statistically lower titers than VLP-vaccinated mice and mice
vaccinated with a 1 μg dose of soluble Envs had undetectable
mucosal anti-Env antibodies.
Virus-like particles broaden the anti-Env antibody responses
Serum samples were assayed for the ability to recognize
individual, overlapping peptides representing the entire
Envgp160. Sera collected from all vaccinated mice recognized
greater than 50% of all the peptides at low levels (<0.2 O.D,
less than 3-fold over background). However, mice vaccinated
with VLPs recognized a larger number of Env-specific
peptides at higher titers compared to mice vaccinated with
soluble envelopes (Fig. 5). Sera from mice vaccinated with
soluble envelopes bound fewer than 9 peptides with a titer
that was greater than 3-fold over background (non-specific
peptides, as well as sera from naïve mice) (Figs. 5A and B).In contrast, collected sera from HIV-1 VLP-vaccinated mice
recognized 40 peptides with a titer that was 3-fold over
background (Fig. 5C). Sera from VLP-vaccinated mice
recognized peptides in both gp120 and gp41 and sera from
mice vaccinated with gp140, which contained the ectodomain
of gp41, did not recognize any of the peptides representing
gp140.
Even though peptides were recognized by sera from VLP-
vaccinated mice throughout Env at high titers, there did
appear to be hotspots of recognition. Peptides overlapping the
cleavage site, representing the V4-C5 regions in gp120 and
the amino terminal region of gp41, were specifically
recognized by this serum (Fig. 5). Interestingly, sera from
VLP-vaccinated mice also recognized peptides in gp41 that
overlap the highly cross-reactive Kennedy epitope. A few
specific peptides were recognized by sera from VLP-
vaccinated mice to regions in C2. Lower titer antibodies (2-
to 3-fold over background; <0.2 O.D.) recognized several
peptides in V1, V2, and C2, but few high titer antibodies
(greater than 3-fold over background; >0.2 O.D.) recognized
peptides in V1 or V2 and no peptides were detected to V3.
Sera from mice vaccinated with Envgp120 did detect three V3-
specific peptides at high titers, but Envgp140-vaccinated mice
did not. In contrast, numerous peptides in the V1, V2, C2,
and V3 regions were recognized by antisera at lower titers
Fig. 5. Location in Env corresponding to high titer induced antibodies recognizing linear epitopes. Relative peptide location in the Env amino acid sequence detected
by antiserum from each vaccinated mouse group that had an O.D. value greater than 3-fold over background. Background was measured as the O.D. value against
irrelevant peptide (a Nef peptide) or the reactivity of sera from naïve, age-matched mice. (A) gp120, (B) gp140, (C) HIV VLP. Bottom schematic displays regions of
Env, the variable regions (gray), and the transmembrane domain (black).
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lopes (data not shown).
Neutralization activity
Sera were examined for the ability to neutralize virus
infection in vitro (Montefiori, in press) against both
neutralization-sensitive and neutralization-resistant viral iso-
lates (Table 1). Sera from mice vaccinated intranasally with
HIV-1 VLPs had antibodies that neutralized both homologousand heterologous virus isolates (50% inhibition, no IC90
values detected). The R5 isolates representing early transmis-
sion (CAAN5342.A2, PVO.4, and THRO4156.18) were more
difficult to neutralize than YU-2 or ADA. The dual-tropic
isolate, 89.6, was consistently the more easily neutralized
isolate and the only isolate neutralized with sera from mice
vaccinated with soluble envelopes (Table 1). Sera from mice
vaccinated with Gagp24 only did not neutralize any of the
viral isolates (data not shown). In addition, the antibodies in
the sera from VLP-vaccinated mice were specific for Env,
339S.P. McBurney et al. / Virology 358 (2007) 334–346since the sera from these mice neutralized viruses with HIV-1
Env and did not neutralize viruses pseudotyped the MuLV
Env (Table 1).
Discussion
In this study, HIV-1 virus-like particles were expressed from
a single gene insert lacking the sequences for LTRs, IN, Vpr,
Vif, and Nef that was engineered with safety mutations in CAp24
and RT to prevent viral RNA packaging and reverse
transcriptase activity (Young et al., 2004). The VLPs were
produced from a virally regulated modified proviral genome
that resulted in a self-assembling, non-replicating, non-
pathogenic, genomeless particle that was similar in size and
conformation to intact virions. These VLP immunogens can be
administered as purified particles or expressed in vivo from
DNA plasmids/viral vectors (for reviews, see references (Doan
et al., 2004; Young and Ross, 2003)). Only a few systems have
been developed that utilize the viral regulatory mechanisms of a
lentiviral genome to express particles in primate cells (Smith et
al., 2003; Young et al., 2004).
Mice inoculated intranasally with these HIV-1 VLPs elicited
robust cellular responses to Gag, Pol, and Env gene products
(Fig. 2). Soluble forms of Env were administered at doses 10- to
100-fold higher than the Env on the VLP, yet elicited few
cellular responses. Both VLPs and soluble envelopes did elicit
robust anti-Env serum antibody (Fig. 3), however, mice
vaccinated with VLPs elicited antibodies that recognized a
broader number of Env-specific peptides at higher titers than
sera from mice vaccinated with soluble envelopes (Fig. 5). In
addition, only mice vaccinated with VLPs had high mucosal
anti-Env antibodies (Fig 4). Despite similar anti-Env IgG serum
titers (Fig. 3), only mice vaccinated with VLPs had antibodies
that blocked viral infection of neutralization-resistant viruses in
an in vitro neutralization assay (Table 1). Therefore, the
presentation of native forms of envelope in the context of a
viral membrane to the immune system elicited significantly
broader immunity than soluble forms of envelope following
mucosal vaccination.
The goal of this study was to determine if envelope,
presented to the immune system on the surface of a viral
particle, is a more effective immunogen than soluble forms of
Env. The role of Env appears critical for the induction of
protective efficacy by recent AIDS vaccines (Amara et al.,
2002; Letvin et al., 2004). Non-human primates immunized
with Gag only vaccines do not control viral infection as well as
the same vaccine that included Env (Amara et al., 2002).
However, the specific immune mechanism(s) associated with
Env in those vaccines has not been determined, but most likely
is associated with anti-Env cellular and antibody responses.
Envelope on the native virion is predicted to form a trimer
(Chan et al., 1997; Farzan et al., 1998; Hill et al., 1996; Tan et
al., 1997). Therefore, our laboratory and others have used
soluble, oligomeric/trimeric forms of Env to mimic the
proposed native trimeric structure of Env on the viral membrane
in order to elicit cross-reactive immunity and induce con-
formationally dependent antibodies that recognize epitopespresent only on the native virion-associated envelopes (Bed-
dows et al., 2005; Bower et al., 2004; Center et al., 2001;
Grundner et al., 2005; Pancera et al., 2005; Pancera and Wyatt,
2005; Rao et al., 2004; Sanders et al., 2002; Yang et al., 2000,
2002). These uncleaved oligomeric Env proteins do elicit
marginally higher neutralizing antibody titers than monomers of
Env gp120 when administered parenterally (Barnett et al., 2001;
Bower et al., 2004; VanCott et al., 1997; Yang et al., 2001). The
lack of high titer, broadly reactive neutralizing antibodies
elicited by these immunogens is associated with the elicitation
of primarily non-neutralizing antibodies (Pancera and Wyatt,
2005; Schulke et al., 2002; Si et al., 2003).
Even though all the vaccines in this study elicited serum anti-
Env antibodies, the envelope-bound VLPs elicited higher titers
of both mucosal antibodies (Fig. 4) and serum antibodies that
recognized a broader range of linear Env epitopes following
intranasal administration (Fig. 5). Similar titers were elicited
using a monomeric Envgp120 or trimeric Envgp140 expressed in a
DNA prime/protein boost by intramuscular injection (Bower et
al., 2005, 2004). These results are supported by a recent study
from Grundner et al. (2005) that demonstrated Envgp140
cleavage-defective trimers (similar to the Envgp140 trimers
used in this study) are more effective at generating neutralizing
antibodies when presented on a solid phase proteoliposomes,
indicating that the Envgp140 trimer presented on the surface of a
lipid bilayer is a more effective immunogen than non-
membrane-bound Env trimers. However, there are most likely
considerable differences between cleaved Envgp160 trimers on
our VLPs and uncleaved Envgp140 trimers, even when presented
on a lipid membrane.
Linear antibodies elicited in VLP-vaccinated mice were
directed to regions in gp120 outside V3, similar to sera from
mice vaccinated with Envgp140 proteoliposomes (Grundner et
al., 2005). The role of the V3 region in eliciting neutralizing
antibodies has been controversial. Even though V3-specific
antibodies can neutralize T-cell-adapted (TCLA) HIV-1 isolates
by recognizing a linear site (GPGR/Q), they do tend to be strain-
specific (Spenlehauer et al., 1998; York et al., 2001). V3-
specific antibodies are often elicited using Envgp120 monomers
due to sequence accessibility on gp120, but this region is less
accessible in oligomeric forms of Env (Bou-Habib et al., 1994;
Spenlehauer et al., 1998; Stamatatos and Cheng-Mayer, 1995)
and may be less accessible in primary HIV-1 isolates (Burton et
al., 2004; Spenlehauer et al., 1998; Wyatt and Sodroski, 1998).
Even though few V3-specific linear epitopes were recognized at
high titers by sera from mice vaccinated with VLPs, we cannot
rule out that antibodies did recognized conformational epitopes
in V3. Sera from both soluble Env- and VLP-vaccinated mice
were tested in a concanalvin A (Con A) capture ELISA. All
serum samples retained high endpoint dilution titers to gp120
(>1:10000), indicating that the sera contained antibodies that
recognized both conformational epitopes on Env, as well as
linear epitopes. The elicited anti-Env antibodies did recognize a
cluster of peptides just before (V4-C5 region in gp120) and just
after (ectodomain of gp41) the cleavage site.
At lower titers, sera from both soluble Env- or VLP-
vaccinated mice recognized peptides throughout gp120,
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peptides were detected at high titers. Three immunodominant
peptides in V2 were detected in all VLP- and soluble Env-
vaccinated mice (peptide 47, representing NDNTSSYR-
LISCNTS and peptides 57–58, representing ILKCNDKKF-
NGTGPCTNVS). Even though antibodies directed to V1, V2,
and/or V3 have been shown to be potent in neutralizing virus in
in vitro infection assays (Fung et al., 1992; Gorny et al., 1994;
Putney et al., 1986), the role of these antibodies in protection is
unclear and controversial (Calarese et al., 2003; Fung et al.,
1992; Gorny et al., 1994, 1997, 1991, 1993; Trkola et al., 1996).
An interesting set of peptides detected by sera from VLP-
vaccinated mice was the highly cross-reactive Kennedy epitope
(residues 731–752, SRFPDRPEGTEEEGGERDRDRS) locat-
ed in a region classified as the intra-cytoplasmic domain (ICD)
of gp41 (Kennedy et al., 1986). It has been widely assumed that
the ICD is located completely within the inner leaflet of the viral
or cellular lipid bilayer. However, neutralizing antibodies are
directed to the Kennedy epitope (Cleveland et al., 2000, 2003;
Kennedy et al., 1986; Modrow et al., 1987; Reading et al.,
2003), and at least part of the Kennedy epitope, in the context of
intact virions, is reactive with specific monoclonal antibodies
and susceptible to protease digestion, consistent with ICD
virion or infected cell exposure. Based on antigenic properties
and a theoretical structural analyses of Envgp41 ICD sequences
from various HIV-1 clades (357 sequences), Hollier and
Dimmock recently proposed that ICD sequences potentially
form a tail loop structure supported by three β-sheet membrane
spanning domains (Hollier and Dimmock, 2005). Therefore,
antibodies directed at this region in Envgp41 would only be
elicited by Envgp160 molecules found in particle-based vaccines
or from Envgp160 expressed in vivo from DNA plasmids or viral
vectors.
We chose to use a mouse model for these studies primarily
because this small animal model allows for detailed analysis of
both cellular and humoral immunity induced by these VLP
vaccines. However, one limitation of sera collected from mice is
the intrinsic high titers of non-specific background observed in
in vitro neutralization assays. Despite these limitations, sera
collected from VLP-vaccinated mice were able to neutralize
both neutralization-sensitive and neutralization-resistant viral
isolates (Table 1). Mice vaccinated intranasally with either
soluble monomeric Envgp120 or trimeric Envgp140 had neutral-
izing antibodies to only 89.6. Even though our laboratory and
others have demonstrated that trimeric Envgp140 elicits modest
levels of neutralizing antibodies, the lack of neutralizing
antibodies from soluble Env-vaccinated mice may be a result
of the route of inoculation [mucosal (intranasal) vs. parenteral
(intramuscular/intradermal)]. The neutralizing capacity of sera
collected from VLP-vaccinated mice was specific for the HIV-1
envelope, since this serum did not neutralize virus pseudotypes
with MuLV Env (Table 1). These HIV-1 Env-specific
neutralizing antibody titers were above the background
neutralizing antibodies directed against cellular monkey
proteins embedded in the VLP membrane, since sera from
mice vaccinated with Gag only particles (no envelope) elicited
few antibodies, which were subtracted from the final analysis.Recently, Hammonds et al. recorded high levels of neutralizing
antibodies to cellular embedded proteins in VLP-vaccinated
guinea pigs following intramuscular injection (Hammonds et
al., 2005), but significant neutralizing titers were still present
following depletion of the non-specific neutralizing antibodies.
The reasons for the differences in neutralizing capacity in the
sera from these two studies are unclear, but may be due to the
route of inoculation (intranasal vs. intramuscular), the amount
of Env on each of the particles, the animal species used (mice
vs. guinea pigs), or the phenotype of the envelope isolates used
(Li et al., 2005). These differences are unlikely a result of the
neutralization assay used, since both studies used the same
TZM-bl assay (Li et al., 2005). No neutralizing antibodies were
detected in the lung washes from our vaccinated mice, which
may be directly due to the mouse model used or the low titers of
mucosal antibodies detected (Fig. 4). Future studies in larger
rodents (rabbits or guinea pigs) or non-human primates will be
necessary to determine if VLPs elicit neutralizing antibodies in
mucosal tissues.
Why might the VLPs described in this study be such
effective mucosal immunogens? Compared to particulate
antigens, intranasal vaccination of soluble proteins, in the
absence of an adjuvant, induces low or undetectable immune
responses in rodents and primates (Tochikubo et al., 1998).
Intranasal immunization of VLPs induces both systemic and
mucosal immunity. Soluble antigens can penetrate the nasal
epithelium and directly interact with dendritic cells, macro-
phages and lymphocytes and then these antigens are transferred
to posterior lymph nodes (Tilney, 1971). In contrast, VLPs are
most likely phagocytosed by microfold epithelial cells (M
cells) in the nasal lumen and then directly deposited to the
NALT (nasal associated lymphoid tissue) via M cell transcy-
tosis (Wu et al., 1997), which preferentially drains into lymph
nodes. This process induces strong local (NALT) and distant
immune responses in both peripheral and mucosal immune
compartments (Sminia and Draal, 1999). Soluble antigens
bypass the NALT and are directly fed into superficial lymph
nodes by antigen presenting cells in the nasal lumen resulting
in a lower local immune response (Sminia and Draal, 1999).
Therefore, VLP immunogens directly interact with the mucosal
immune system to elicit high titer immunity. Overall, the
expression of Env in any HIV/AIDS vaccine may elicit a
variety of potentially effective protective immunity depending
on the structure of the protein presented to the immune system.
Following mucosal administration, the membrane-bound Env
on the surface of a particle appears more effective at eliciting
immunity that specifically recognizes Env on the native particle




The pTR600 vaccine plasmid (Green et al., 2003) and the
VLP expressing plasmid, pHIV-VLP, have been previously
described (Young et al., 2004). Briefly, the pTR600 vector was
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promoter (CMV-IE) for initiating transcription of eukaryotic
inserts and the bovine growth hormone polyadenylation signal
(BGH poly A) for termination of transcription. The vector
contains the Col E1 origin of replication for prokaryotic
replication and the kanamycin resistance gene (kanr) for
selection in antibiotic media.
The pHIV-VLP plasmid (Young et al., 2004) encodes for the
following gene sequences: HIV-1BH10 gag–pol (pHIVBH10 nt
112–3626) (accession number M1564) and HIV-1ADA vpu, env,
rev, tat (nt 5101–8159). Briefly, the pHIV-VLP was constructed
from two subclones encoding for the 5′ end of the VLP gene
insert (5′-ClaI and 3′-EcoRI) and a second subclone encoding
for the 3′ end of the VLP gene insert (5′-EcoRI and 3′-NheI).
Oligonucleotides corresponding to the gag–pol sequences were
used in a PCR reaction to amplify a fragment of DNA (5′ PCR
product) composed of the 5′ untranslated leader sequence (105
nucleotides) and gag–pol sequences (ATG start codon of gag to
the TAG stop codon at the 3′ end of the reverse transcriptase
sequence, pHIVBH10 nt 112–3626). Both of the 5′ and 3′ PCR
products were cloned into pTR600 using unique restriction
enzymes sites (5′ PCR product: ClaI and EcoRI and the 3′ PCR
product using EcoRI and NheI). The splice–acceptor sites were
not mutated to allow for efficient mRNA processing of singly
and multiply spliced messenger RNAs. The previously
described safety mutations were introduced into the VLP
vaccine insert by PCR-based mutagenesis (Stratagene, La Jolla,
CA) to delete RT activity, RNase H activity, and packaging of
RNA genome (Young et al., 2004).
Plasmids expressing the HIV-1NL4-3 Gag gene products only,
pGagp55, were derived from codon-optimized sequences
(phGag), as previously described (Huang et al., 2001; Young
et al., 2004). pGagp55 encodes for an immature, unprocessed
HIV-1 Gag particle. The plasmids, pEnvgp120 and pEnvgp140(FT),
encode for soluble forms of monomeric Envgp120 or trimeric
Envgp140 from the isolate ADA (Bower et al., 2005, 2004). Each
plasmid was amplified in Escherichia coli strain-DH5 alpha,
purified using anion-exchange resin columns (Qiagen, Valencia,
CA), and stored at −20 °C in dH2O. Plasmids were verified by
appropriate restriction enzyme digestion and gel electrophore-
sis. Purity of DNA preparations was determined by optical
density reading at a wavelength of 260 and 280 nm.
Transfections and expression analysis
The monkey fibroblast cell line COS (5×105 cells/
transfection) was transfected with 2 μg of DNA using 12%
lipofectamine according to the manufacturer's guidelines (Life
Technologies, Grand Island, NY). Supernatants (2 ml) were
collected and stored at −20 °C. Cell lysates were collected in
500 μl of 1% Triton X-100 and stored at −20 °C. Quantitative
antigen capture ELISAs were conducted according to the
manufacturer's protocol (Perkin-Elmer Life Sciences, Boston,
MA). For Western hybridization analysis, 3.3% of supernatant
and 1.5% of the cell lysate were diluted 1:2 in SDS sample
buffer (Bio-Rad, Hercules, CA), boiled for 5 min, and loaded
onto a 10% polyacrylamide/SDS gel. The resolved proteinswere transferred onto a nitrocellulose membrane and incubated
with a 1:10000 dilution of polyclonal antisera using HIV-Ig to
detect HIV-1 antigens diluted in PBS containing 0.05% Tween
20 and 5% nonfat dry milk. After extensive washing, bound
human antibodies were detected using a 1:10000 dilution of
horseradish peroxidase-conjugated goat anti-human antiserum,
followed by enhanced chemiluminescence (Amersham, Buck-
inghamshire, UK).
Purification of virus-like particles and soluble envelopes
Supernatants from COS cells, transiently transfected with
plasmid expressing Gag or VLPs were pelleted via ultracentri-
fugation (100,000×g through 20% glycerol, weight per
volume) for 2 h at 4 °C. The pellets were subsequently
resuspended in PBS and overlaid onto 20–60% sucrose
gradients (11 steps, 4% increments) and ultracentrifuged for
17 h at 100,000×g at 4 °C. Eleven fractions (20–60%, 1 ml,
weight per volume) were collected top to bottom from the
gradient, and the proteins were precipitated with equal volumes
of 20% trichloroacetic acid (TCA) and subjected to SDS-PAGE
and immunoblotting. The viral proteins were detected by
primary antisera via Western hybridization. Determination of
the amount of Gag and Env protein on the particle was
determined by ELISA, as previously described (Smith et al.,
2004). Soluble monomeric Envgp120 or trimeric Envgp140 was
purified from the supernatant of transiently transfected COS
cells by a lectin column and resuspended in 0.9% saline for
inoculation.
Immunization of mice
Female BALB/c mice (n=6, 5–7 weeks old) were
immunized at weeks 0, 3, and 6 with purified VLPs (40 μg
total protein) and co-inoculated with phosphorothioate CpG
oligodeoxynucleotides (CpG ODNs, 10 μg each) via the nares.
Each CpG ODN (ODN-1: 5′-TCCATGACGTTCCTGACGTT-
3′, ODN-2: 5′-TGACTGTGAACGTTCGAGATGA-3′) (Galli-
chan et al., 2001; Horner et al., 1998; Kang and Compans, 2003;
McCluskie and Davis, 1998; Moldoveanu et al., 1999) was
synthesized and purified by high-pressure liquid chromatogra-
phy (Sigma-Genosys, The Woodlands, TX, USA). The CpG
ODNs were resuspended in sterile dH2O (2 μg/μl) and stored at
−80 °C. Each purified VLP preparation was analyzed for purity
by silver staining of an SDS-PAGE and ∼80–90% of the
protein in the purified preparation was Gag gene products and
therefore, mice were administered∼0.5–1.0 μg of Env per VLP
immunization. Mice were administered VLPs in sterile PBS
plus CpG ODNs into the nares of each mouse (30 μl total
volume). Supernatants from primate cells transiently transfected
with the vector, pTR600, were ultracentrifuged through 20%
glycerol. For intranasal inoculation, the pellet was resuspended
in sterile PBS plus CpG ODNs and inoculated into the naïve
mice (equivalent volume compared to mice given a VLP
inoculum). Mice vaccinated with Envgp140 or Envgp120 were
given 1 μg or 10 μg of protein with the same concentration of
CpG ODNs in PBS. Proteins were purified from the supernatant
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HIS-tagged envelopes (Bower et al., 2005, 2004). Gagp24 was
purified by the same ultracentrifugation procedure as VLPs.
Mice were administered the same amount of Gagp24 plus CpG
ODNs to match the Gagp24 in the VLP inoculations (40 μg).
Mice were housed in compliance with USDA regulations and
were monitored daily for weight loss, behavior, and adverse
reaction. Mice were partially anesthetized with xylazine
(20 mg/ml) and ketamine (100 mg/ml) administered subcuta-
neously in the abdomen prior to immunization.
Collection of samples
Blood samples were collected by retro-orbital plexus
puncture on day 1 and weeks 2, 5, and 8 post-immunization
on anesthetized mice. Sera samples were collected by
centrifugation (5000 rpm, 10 min) and stored at −20 °C.
Mucosal washings were collected at week 9 post-immunization.
Vaginal lavages were collected by repeated rinsing of the vagina
(200 μl) with sterile PBS. The lungs were excised and cut into
small pieces using a sterile scalpel in sterile PBS (200 μl). The
lung tissue pieces were centrifuged (12,000 rpm, 5 min), and
supernatants were collected. A section of the intestines (1.3 cm)
was aseptically removed and placed in sterile PBS (200 μl). The
collected fecal samples were disrupted using a sterile pipet tip,
vortexed (15 s), centrifuged (12,000 rpm for 5 min), and the
product supernatants were collected. The protein concentration
of the fecal supernatants was adjusted to a final concentration of
1 mg/ml with sterile PBS. All samples were stored at −80 °C.
ELISpot assays
Spleens were harvested from vaccinated mice at week 8, and
splenocytes were isolated for ELISpot assays, as previously
described (Bower et al., 2005, 2004). Briefly, splenocytes were
depleted of erythrocytes by treatment with ammonium chloride
(0.1 M, pH 7.4). Following thorough washing with PBS, cells
were resuspended inRPMImediumwith 10% fetal bovine serum
(cRPMI). Cell viability was determined by trypan blue exclusion
staining. The number of anti-Gag, anti-Pol, or anti-Envgp160-
specific murine INF-γ (mINF-γ) secreting splenocytes was
determined by enzyme-linked immunospot (ELISpot) assay
(R&D Systems, Minneapolis, MN, USA). Briefly, pre-coated
anti-mIFN-γ plates were incubated (25 °C for 2 h) with cRPMI
(200 μl) and then were incubated with splenocytes (1×106/well)
isolated from vaccinated mice. Splenocytes were stimulated
(48 h) with peptides (AIDS Reagent and Reference Program)
representing the consensus clade B Gag or Pol regions. For Env,
four pools of peptides were used, (1) a pool of 10 peptides
representing the C1 region of Env (amino acids 32–79), (2) a
pool of 4 peptides representing theV3 region of Env (amino acids
294–314), (3) a pool of 99 peptides representing the gp120
region (amino acids 52–455) or (4) a pool of 99 peptides
representing the gp41 region (amino acids 444–840) of the
consensus Group M Env protein. The V3 regions peptides were
specific to the sequence for the isolates,MN, IIIB, the subtype B,
and the consensus B sequences. The subtype B and consensus Bmatch theV3 loop ofADA.Additional wells of splenocytes were
stimulated with PMA (50 ng)/ionomycin (500 ng) or were mock
stimulated. In addition, IL-2 was added to all wells (10 units/ml).
Plates were washed with PBS–Tween (3×) and were incubated
(25 °C for 2 h) with biotinylated anti-mIFN-γ and incubated
(4 °C for 16 h). The plates were washed and incubated (25 °C for
2 h) with streptavidin conjugated to alkaline phosphatase.
Following extensive washing, cytokine/antibody complexes
were incubated (25 °C for 1 h) with stable BCIP/NBT
chromogen. The plates were rinsed with dH2O and air dried
(25 °C for 2 h). Spots were counted by an ImmunoSpot ELISpot
reader (Cellular Technology Ltd., Cleveland, OH, USA).
Antibody response to VLP immunizations
Serum and mucosal samples were individually collected and
tested for antibody (IgG or IgA) responses to Env by ELISA.
HIV-1ADA Envgp120 was purified from the supernatants
collected from 293T cells transiently transfected with a plasmid
that expressed the HIV-1ADA Envgp120 from codon optimized
gene inserts. Each well of a 96-well plate was coated with 50 ng
Envgp120 per well (4 °C for 16 h). Plates were blocked (25 °C for
2 h) with PBS containing Tween 20 (0.05%) and nonfat dry
milk (5%) and then incubated with serial dilutions of each
sample (sera or mucosal washings) (25 °C for 2 h). Following
thorough washing in PBS–Tween 20 (0.05%), samples were
incubated (25 °C for 1 h) with goat anti-mouse IgG conjugated
to horseradish peroxidase (HRP) diluted 1:5000 in PBS–Tween
20 (0.05%) and nonfat dry milk (5%). The unbound antibody
was removed, and the wells were washed. Samples were
incubated with TMB substrate (1 h), and the colorimetric
change was measured as the optical density (O.D., 405 nm) by a
spectrophotometer (Dynex Technologies, Chantilly, VA, USA).
The O.D. value of naïve sera and sera from mice vaccinated
with virus-like particles composed of only Gag gene products
(no Env) was subtracted from the samples using antisera from
vaccinated mice. Results were recorded as the arithmetic
mean± the standard deviation (SD). In order to measure the
level of HIV-1 Env-specific IgG subtypes, biotinylated goat
anti-mouse IgG1 or IgG2a (1:5000) antibodies were used to
detect Env-antibody complexes.
Mapping of specific antibodies by poly-L-lysine peptide ELISA
Antibody reactivity to HIV peptides was determined using a
poly-L-lysine (PLL) peptide ELISA, as previously described
(Ball et al., 1994; Cole et al., 2000; Miller et al., 1992). Briefly,
the wells of Immulon 1B microtiter plates (Dynex Corporation,
McLean, VA) were coated with 2 μg per well of PLL (Sigma, St.
Louis, MO) diluted in 0.05 M sodium bicarbonate buffer (pH
9.6) and incubated for 1 h at 25 °C. Peptides were diluted to
50 μg/ml in 0.05 M sodium bicarbonate buffer (pH 9.6) were
then fixed onto PLL-coated wells by incubating 50 μl per well
overnight at 25 °C. After ∼16 h, all wells were washed and
blocked with 100 μl of glycine (1 M) followed by 0.5% nonfat
dry milk/0.5% gelatin for 1 h each at room temperature. Serum
was diluted 1:3000 in 5% nonfat dry milk and incubated for 1
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incubated with goat anti-mouse IgG-HRP diluted 1:5000 in 5%
nonfat dry milk for 1 h at 25 °C. Specific reactivity was detected
by the addition of 100 μl TMB substrate (Sigma, St. Louis, MO,
USA). The reaction was stopped by the addition of 50 μl of
sulfuric acid (1 N) and read as O.D. at 450 nm. Antibody
reactivity was then reported as the O.D. at 450 nm at 1:3000
dilution of sera.
Pseudovirus preparation
HIV-1 viral cores were pseudotyped with envelopes
representing primary R5 isolates (ADA, YU-2, CAAN5342.
A2, PVO.4, and THRO4156.18) or R5X4 isolates (89.6).
Briefly, 293T cells were transfected with 5 μg of Env encoding
plasmid and 10 μg of an Env-deficient HIV-1 backbone vector
(pSG3Δenv) using Lipofectamine 2000 (Invitrogen) (Li et al.,
2005). Virus-containing supernatant was collected 48 h post-
transfection, clarified of cellular debris by centrifugation
(14,000 rpm for 10 min) and stored at −80 °C in 1 ml aliquots.
TCID50 was determined using 5-fold dilutions of virus. Eight
hours prior to infection, TZM-bl cells were plated at a
concentration of 1×104 cells per well. Cells were incubated
with serial dilutions of virus for 48 h at 37 °C in 5% CO2. Cell
lysates were harvested and incubated (20 min) in lysis buffer
(25 mM Tris phosphate, pH=7.8, 2 mM DTT, 2 mM 1-2-
diaminocyclohexane-N,N,N′,N′-tetraacetic acid, 10% glycerol,
1% Triton X-100). Infectivity was determined by measuring the
relative light units (RLU) using a Femtomaster FB12
Luminometer (Zylux, Maryville, TN). The TCID50 was
calculated from the RLU values.
Neutralization assay
Antisera from vaccinated mice were tested for the ability
to neutralize virus infection in vitro using TZM-bl cells
indicator cells (Li et al., 2005; Montefiori, in press). These
cells express human CD4 (hCD4), human CCR5 (hCCR5),
human CXCR4 (hCXCR4), and a luciferase reporter driven
by the HIV-1 LTR. TZM-bl cells were cultured in cDMEM
with 10% fetal calf serum (10%) (Atlanta Biologicals,
Atlanta, GA, USA). TZM-bl cells were plated at a
concentration of 1×104 cells per well and incubated in
DMEM with 10% FCS (8 h). Equal volumes of serial
dilutions of each antiserum and pseudovirus were incubated
for at least 1 h at 37 °C. Media was removed from the TZM-
bl cells and replaced with the antiserum/pseudovirus mixture.
The cells were then incubated for 48 h at 37 °C in 5% CO2.
Cell lysates were harvested and incubated in lysis buffer
(20 min). Virus neutralization by mouse antiserum was
determined by measuring the relative light units (RLU) using
a Femtomaster FB12 Luminometer (Zylux, Maryville, TN).
Neutralization by naïve sera and sera from mice vaccinated
with virus-like particles composed of only Gag gene products
(no Env) or MuLV Env was subtracted from the RLU from
assays using antisera from vaccinated mice. All samples were
tested in duplicate.Acknowledgments
This research was supported by National Institute of Health
Grant AI51213 to T.M.R. The authors thank Franklin Toapanta
and Heather Grieser for their technical assistance, and Kelly
Stefano Cole and Ronald C. Montelaro for their helpful
discussions. The following peptides and the following reagents
were obtained through the AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, NIH: TZM-bl
cells (also called JC57BL-13) (#8129), HIV-1ADA (#416), HIV-
Ig (#3957, from NABI and NHLBI).
References
Adams, O., Scheid, A., 2001. Stepwise deletion of the HIV type 1 glycoprotein
41 N terminus leads to an increasing export of microvesicles containing
uncleaved Env glycoprotein. AIDS Res. Hum. Retroviruses 17 (14),
1345–1356.
Amara, R.R., Villinger, F., Altman, J.D., Lydy, S.L., O'Neil, S.P., Staprans, S.I.,
Montefiori, D.C., Xu, Y., Herndon, J.G., Wyatt, L.S., Candido, M.A., Kozyr,
N.L., Earl, P.L., Smith, J.M., Ma, H.L., Grimm, B.D., Hulsey, M.L., Miller,
J., McClure, H.M., McNicholl, J.M., Moss, B., Robinson, H.L., 2001.
Control of a mucosal challenge and prevention of AIDS by a multiprotein
DNA/MVA vaccine. Science 292 (5514), 69–74.
Amara, R.R., Smith, J.M., Staprans, S.I., Montefiori, D.C., Villinger, F., Altman,
J.D., O'Neil, S.P., Kozyr, N.L., Xu, Y., Wyatt, L.S., Earl, P.L., Herndon,
J.G., McNicholl, J.M., McClure, H.M., Moss, B., Robinson, H.L., 2002.
Critical role for Env as well as Gag-Pol in control of a simian-human
immunodeficiency virus 89.6P challenge by a DNA prime/recombinant
modified vaccinia virus Ankara vaccine. J. Virol. 76 (12), 6138–6146.
Ball, J.M., Henry, N.L., Montelaro, R.C., Newman, M.J., 1994. A versatile
synthetic peptide-based ELISA for identifying antibody epitopes.
J. Immunol. Methods 171 (1), 37–44.
Barnett, S.W., Lu, S., Srivastava, I., Cherpelis, S., Gettie, A., Blanchard, J.,
Wang, S., Mboudjeka, I., Leung, L., Lian, Y., Fong, A., Buckner, C., Ly, A.,
Hilt, S., Ulmer, J., Wild, C.T., Mascola, J.R., Stamatatos, L., 2001. The
ability of an oligomeric human immunodeficiency virus type 1 (HIV-1)
envelope antigen to elicit neutralizing antibodies against primary HIV-1
isolates is improved following partial deletion of the second hypervariable
region. J. Virol. 75 (12), 5526–5540.
Beddows, S., Schulke, N., Kirschner, M., Barnes, K., Franti, M., Michael, E.,
Ketas, T., Sanders, R.W., Maddon, P.J., Olson, W.C., Moore, J.P., 2005.
Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric
form of the envelope glycoprotein complex of human immunodeficiency
virus type 1. J. Virol. 79 (14), 8812–8827.
Bou-Habib, D.C., Roderiquez, G., Oravecz, T., Berman, P.W., Lusso, P.,
Norcross, M.A., 1994. Cryptic nature of envelope V3 region epitopes
protects primary monocytotropic human immunodeficiency virus type 1
from antibody neutralization. J. Virol. 68 (9), 6006–6013.
Bower, J.F., Yang, X., Sodroski, J., Ross, T.M., 2004. Elicitation of neutralizing
antibodies with DNA vaccines expressing soluble stabilized human
immunodeficiency virus type 1 envelope glycoprotein trimers conjugated
to C3d. J. Virol. 78 (9), 4710–4719.
Bower, J.F., Sanders, K.L., Ross, T.M., 2005. C3d enhances immune responses
using low doses of DNA expressing the HIV-1 envelope from codon-
optimized gene sequences. Curr. HIV Res. 3 (2), 191–198.
Burton, D.R., Desrosiers, R.C., Doms, R.W., Koff, W.C., Kwong, P.D., Moore,
J.P., Nabel, G.J., Sodroski, J., Wilson, I.A., Wyatt, R.T., 2004. HIV vaccine
design and the neutralizing antibody problem. Nat. Immunol. 5 (3),
233–236.
Calarese, D.A., Scanlan, C.N., Zwick, M.B., Deechongkit, S., Mimura, Y.,
Kunert, R., Zhu, P., Wormald, M.R., Stanfield, R.L., Roux, K.H., Kelly,
J.W., Rudd, P.M., Dwek, R.A., Katinger, H., Burton, D.R., Wilson, I.A.,
2003. Antibody domain exchange is an immunological solution to
carbohydrate cluster recognition. Science 300 (5628), 2065–2071.
Center, R.J., Schuck, P., Leapman, R.D., Arthur, L.O., Earl, P.L., Moss, B.,
344 S.P. McBurney et al. / Virology 358 (2007) 334–346Lebowitz, J., 2001. Oligomeric structure of virion-associated and soluble
forms of the simian immunodeficiency virus envelope protein in the
prefusion activated conformation. Proc. Natl. Acad. Sci. U.S.A. 98 (26),
14877–14882.
Chakrabarti, B.K., Ling, X., Yang, Z.Y., Montefiori, D.C., Panet, A., Kong,
W.P., Welcher, B., Louder, M.K., Mascola, J.R., Nabel, G.J., 2005.
Expanded breadth of virus neutralization after immunization with a
multiclade envelope HIV vaccine candidate. Vaccine 23 (26), 3434–3445.
Chan, D.C., Fass, D., Berger, J.M., Kim, P.S., 1997. Core structure of gp41 from
the HIV envelope glycoprotein. Cell 89 (2), 263–273.
Chertova, E., Bess Jr., J.W., Crise, B.J., Sowder, I.R., Schaden, T.M., Hilburn,
J.M., Hoxie, J.A., Benveniste, R.E., Lifson, J.D., Henderson, L.E., Arthur,
L.O., 2002. Envelope glycoprotein incorporation, not shedding of surface
envelope glycoprotein (gp120/SU), Is the primary determinant of SU
content of purified human immunodeficiency virus type 1 and simian
immunodeficiency virus. J. Virol. 76 (11), 5315–5325.
Cleveland, S.M., Buratti, E., Jones, T.D., North, P., Baralle, F., McLain, L.,
McInerney, T., Durrani, Z., Dimmock, N.J., 2000. Immunogenic and
antigenic dominance of a nonneutralizing epitope over a highly conserved
neutralizing epitope in the gp41 envelope glycoprotein of human
immunodeficiency virus type 1: its deletion leads to a strong neutralizing
response. Virology 266 (1), 66–78.
Cleveland, S.M., McLain, L., Cheung, L., Jones, T.D., Hollier, M., Dimmock,
N.J., 2003. A region of the C-terminal tail of the gp41 envelope glycoprotein
of human immunodeficiency virus type 1 contains a neutralizing epitope:
evidence for its exposure on the surface of the virion. J. Gen. Virol. 84 (Pt.
3), 591–602.
Cole, K.S., Paliotti, M.J., Murphey-Corb, M., Montelaro, R.C., 2000.
Maturation of envelope-specific antibody responses to linear determinants
in monkeys inoculated with attenuated SIV. J. Med. Primatol. 29 (3–4),
220–230.
Conley, A.J., Kessler II, J.A., Boots, L.J., McKenna, P.M., Schleif, W.A., Emini,
E.A., Mark III, G.E., Katinger, H., Cobb, E.K., Lunceford, S.M., Rouse,
S.R., Murthy, K.K., 1996. The consequence of passive administration of
an antihuman immunodeficiency virus type 1 neutralizing monoclonal
antibody before challenge of chimpanzees with a primary virus isolate.
J. Virol. 70 (10), 6751–6758.
Dettenhofer, M., Yu, X.F., 1999. Highly purified human immunodeficiency virus
type 1 reveals a virtual absence of Vif in virions. J. Virol. 73 (2), 1460–1467.
Doan, L.X., Li, M., Chen, C., Yao, Q., 2004. Virus-like particles as HIV-1
vaccines. Rev. Med. Virol.
Egan, M.A., 2004. Current prospects for the development of a therapeutic
vaccine for the treatment of HIV type 1 infection. AIDS Res. Hum. Retrovir.
20 (8), 794–806.
Ellenberger, D., Li, B., Smith, J., Yi, H., Folks, T., Robinson, H., Butera, S.,
2004. Optimization of a multi-gene HIV-1 recombinant subtype CRF02_AG
DNA vaccine for expression of multiple immunogenic forms. Virology 319
(1), 118–130.
Ellenberger, D., Wyatt, L., Li, B., Buge, S., Lanier, N., Rodriguez, I.V., Sariol,
C.A., Martinez, M., Monsour, M., Vogt, J., Smith, J., Otten, R., Montefiori,
D., Kraiselburd, E., Moss, B., Robinson, H., McNicholl, J., Butera, S., 2005.
Comparative immunogenicity in rhesus monkeys of multi-protein HIV-1
(CRF02_AG) DNA/MVA vaccines expressing mature and immature VLPs.
Virology 340 (1), 21–32.
Farzan, M., Choe, H., Desjardins, E., Sun, Y., Kuhn, J., Cao, J., Archambault,
D., Kolchinsky, P., Koch, M., Wyatt, R., Sodroski, J., 1998. Stabilization of
human immunodeficiency virus type 1 envelope glycoprotein trimers by
disulfide bonds introduced into the gp41 glycoprotein ectodomain. J. Virol.
72 (9), 7620–7625.
Foresman, L., Jia, F., Li, Z., Wang, C., Stephens, E.B., Sahni, M., Narayan, O.,
Joag, S.V., 1998. Neutralizing antibodies administered before, but not after,
virulent SHIV prevent infection in macaques. AIDS Res. Hum. Retrovir. 14
(12), 1035–1043.
Forthal, D.N., Landucci, G., Haubrich, R., Keenan, B., Kuppermann, B.D.,
Tilles, J.G., Kaplan, J., 1999. Antibody dependent cellular cytotoxicity
independently predicts survival in severely immunocompromised human
immunodeficiency virus-infected patients. J. Infect. Dis. 180 (4),
1338–1341.Forthal, D.N., Landucci, G., Daar, E.S., 2001. Antibody from patients with acute
human immunodeficiency virus (HIV) infection inhibits primary strains of
HIV type 1 in the presence of natural-killer effector cells. J. Virol. 75 (15),
6953–6961.
Fung, M.S., Sun, C.R., Gordon, W.L., Liou, R.S., Chang, T.W., Sun, W.N.,
Daar, E.S., Ho, D.D., 1992. Identification and characterization of a
neutralization site within the second variable region of human immunode-
ficiency virus type 1 gp120. J. Virol. 66 (2), 848–856.
Gallichan, W.S., Woolstencroft, R.N., Guarasci, T., McCluskie, M.J., Davis,
H.L., Rosenthal, K.L., 2001. Intranasal immunization with CpG
oligodeoxynucleotides as an adjuvant dramatically increases IgA and
protection against herpes simplex virus-2 in the genital tract. J. Immunol.
166 (5), 3451–3457.
Gardner, M., Rosenthal, A., Jennings, M., Yee, J., Antipa, L., Robinson Jr., E.,
1995. Passive immunization of rhesus macaques against SIV infection and
disease. AIDS Res. Hum. Retrovir. 11 (7), 843–854.
Gomez-Roman, V.R., Patterson, L.J., Venzon, D., Liewehr, D., Aldrich, K.,
Florese, R., Robert-Guroff, M., 2005. Vaccine-elicited antibodies mediate
antibody-dependent cellular cytotoxicity correlated with significantly
reduced acute viraemia in rhesus macaques challenged with SIVmac251.
J. Immunol. 174 (4), 2185–2189.
Gorny, M.K., Xu, J.Y., Gianakakos, V., Karwowska, S., Williams, C., Sheppard,
H.W., Hanson, C.V., Zolla-Pazner, S., 1991. Production of site-selected
neutralizing human monoclonal antibodies against the third variable domain
of the human immunodeficiency virus type 1 envelope glycoprotein. Proc.
Natl. Acad. Sci. U.S.A. 88 (8), 3238–3242.
Gorny, M.K., Xu, J.Y., Karwowska, S., Buchbinder, A., Zolla-Pazner, S., 1993.
Repertoire of neutralizing human monoclonal antibodies specific for the V3
domain of HIV-1 gp120. J. Immunol. 150 (2), 635–643.
Gorny, M.K., Moore, J.P., Conley, A.J., Karwowska, S., Sodroski, J., Williams,
C., Burda, S., Boots, L.J., Zolla-Pazner, S., 1994. Human anti-V2
monoclonal antibody that neutralizes primary but not laboratory isolates
of human immunodeficiency virus type 1. J. Virol. 68 (12), 8312–8320.
Gorny, M.K., VanCott, T.C., Hioe, C., Israel, Z.R., Michael, N.L., Conley, A.J.,
Williams, C., Kessler II, J.A., Chigurupati, P., Burda, S., Zolla-Pazner, S.,
1997. Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and
interclade cross-reactivity. J. Immunol. 159 (10), 5114–5122.
Green, T.D., Montefiori, D.C., Ross, T.M., 2003. Enhancement of antibodies to
the human immunodeficiency virus type 1 envelope by using the molecular
adjuvant C3d. J. Virol. 77 (3), 2046–2055.
Grundner, C., Li, Y., Louder, M., Mascola, J., Yang, X., Sodroski, J., Wyatt, R.,
2005. Analysis of the neutralizing antibody response elicited in rabbits by
repeated inoculation with trimeric HIV-1 envelope glycoproteins. Virology
331 (1), 33–46.
Haigwood, N.L., 2004. Predictive value of primate models for AIDS. AIDS Rev.
6 (4), 187–198.
Haigwood, N.L., Watson, A., Sutton, W.F., McClure, J., Lewis, A., Ranchalis,
J., Travis, B., Voss, G., Letvin, N.L., Hu, S.L., Hirsch, V.M., Johnson, P.R.,
1996. Passive immune globulin therapy in the SIV/macaque model: early
intervention can alter disease profile. Immunol. Lett. 51 (1–2), 107–114.
Hamer, D.H., 2004. Can HIV be cured? Mechanisms of HIV persistence and
strategies to combat it. Curr. HIV Res. 2 (2), 99–111.
Hammonds, J., Chen, X., Ding, L., Fouts, T., De Vico, A., zur Megede, J.,
Barnett, S., Spearman, P., 2003. Gp120 stability on HIV-1 virions and Gag-
Env pseudovirions is enhanced by an uncleaved Gag core. Virology 314 (2),
636–649.
Hammonds, J., Chen, X., Fouts, T., Devico, A., Montefiori, D., Spearman, P.,
2005. Induction of neutralizing antibodies against human immunodeficiency
virus type 1 primary isolates by Gag-Env pseudovirion immunization.
J. Virol. 79 (23), 14804–14814.
Hill, C.P., Worthylake, D., Bancroft, D.P., Christensen, A.M., Sundquist, W.I.,
1996. Crystal structures of the trimeric human immunodeficiency virus type
1 matrix protein: implications for membrane association and assembly. Proc.
Natl. Acad. Sci. U.S.A. 93 (7), 3099–3104.
Hollier, M.J., Dimmock, N.J., 2005. The C-terminal tail of the gp41
transmembrane envelope glycoprotein of HIV-1 clades A, B, C, and D
may exist in two conformations: an analysis of sequence, structure, and
function. Virology 337 (2), 284–296.
345S.P. McBurney et al. / Virology 358 (2007) 334–346Horner, A.A., Ronaghy, A., Cheng, P.M., Nguyen, M.D., Cho, H.J., Broide, D.,
Raz, E., 1998. Immunostimulatory DNA is a potent mucosal adjuvant. Cell.
Immunol. 190 (1), 77–82.
Huang, Y., Kong, W.P., Nabel, G.J., 2001. Human immunodeficiency virus type
1-specific immunity after genetic immunization is enhanced by modification
of Gag and Pol expression. J. Virol. 75 (10), 4947–4951.
Kang, S.M., Compans, R.W., 2003. Enhancement of mucosal immunization
with virus-like particles of simian immunodeficiency virus. J. Virol. 77 (6),
3615–3623.
Kennedy, R.C., Henkel, R.D., Pauletti, D., Allan, J.S., Lee, T.H., Essex, M.,
Dreesman, G.R., 1986. Antiserum to a synthetic peptide recognizes the
HTLV-III envelope glycoprotein. Science 231 (4745), 1556–1559.
Kwong, P.D., Wyatt, R., Robinson, J., Sweet, R.W., Sodroski, J., Hendrickson,
W.A., 1998. Structure of an HIV gp120 envelope glycoprotein in complex
with the CD4 receptor and a neutralizing human antibody. Nature 393
(6686), 648–659.
Letvin, N.L., Huang, Y., Chakrabarti, B.K., Xu, L., Seaman, M.S., Beaudry, K.,
Korioth-Schmitz, B., Yu, F., Rohne, D., Martin, K.L., Miura, A., Kong,
W.P., Yang, Z.Y., Gelman, R.S., Golubeva, O.G., Montefiori, D.C., Mascola,
J.R., Nabel, G.J., 2004. Heterologous envelope immunogens contribute to
AIDS vaccine protection in rhesus monkeys. J. Virol. 78 (14), 7490–7497.
Li, A., Baba, T.W., Sodroski, J., Zolla-Pazner, S., Gorny, M.K., Robinson, J.,
Posner, M.R., Katinger, H., Barbas III, C.F., Burton, D.R., Chou, T.C.,
Ruprecht, R.M., 1997. Synergistic neutralization of a chimeric SIV/HIV
type 1 virus with combinations of human anti-HIV type 1 envelope
monoclonal antibodies or hyperimmune globulins. AIDS Res. Hum.
Retrovir. 13 (8), 647–656.
Li, M., Gao, F., Mascola, J.R., Stamatatos, L., Polonis, V.R., Koutsoukos, M.,
Voss, G., Goepfert, P., Gilbert, P., Greene, K.M., Bilska, M., Kothe, D.L.,
Salazar-Gonzalez, J.F., Wei, X., Decker, J.M., Hahn, B.H., Montefiori, D.C.,
2005. Human immunodeficiency virus type 1 env clones from acute and
early subtype B infections for standardized assessments of vaccine-elicited
neutralizing antibodies. J. Virol. 79 (16), 10108–10125.
Mascola, J.R., Lewis, M.G., Stiegler, G., Harris, D., VanCott, T.C., Hayes, D.,
Louder, M.K., Brown, C.R., Sapan, C.V., Frankel, S.S., Lu, Y., Robb, M.L.,
Katinger, H., Birx, D.L., 1999. Protection of Macaques against pathogenic
simian/human immunodeficiency virus 89.6 PD by passive transfer of
neutralizing antibodies. J. Virol. 73 (5), 4009–4018.
Mascola, J.R., Stiegler, G., VanCott, T.C., Katinger, H., Carpenter, C.B.,
Hanson, C.E., Beary, H., Hayes, D., Frankel, S.S., Birx, D.L., Lewis, M.G.,
2000. Protection of macaques against vaginal transmission of a pathogenic
HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.
Nat. Med. 6 (2), 207–210.
McCluskie, M.J., Davis, H.L., 1998. CpG DNA is a potent enhancer of systemic
and mucosal immune responses against hepatitis B surface antigen with
intranasal administration to mice. J. Immunol. 161 (9), 4463–4466.
McCune, J.M., Rabin, L.B., Feinberg, M.B., Lieberman,M., Kosek, J.C., Reyes,
G.R., Weissman, I.L., 1988. Endoproteolytic cleavage of gp160 is required
for the activation of human immunodeficiency virus. Cell 53 (1), 55–67.
Miller, M.A., Murphey-Corb, M., Montelaro, R.C., 1992. Identification of
broadly reactive continuous antigenic determinants of simian immunodefi-
ciency virus glycoproteins. AIDS Res. Hum. Retrovir. 8 (6), 1153–1164.
Modrow, S., Hahn, B.H., Shaw, G.M., Gallo, R.C., Wong-Staal, F., Wolf, H.,
1987. Computer-assisted analysis of envelope protein sequences of seven
human immunodeficiency virus isolates: prediction of antigenic epitopes in
conserved and variable regions. J. Virol. 61 (2), 570–578.
Moldoveanu, Z., Vzorov, A.N., Huang, W.Q., Mestecky, J., Compans, R.W.,
1999. Induction of immune responses to SIV antigens by mucosally
administered vaccines. AIDS Res. Hum. Retrovir. 15 (16), 1469–1476.
Montefiori, D.C., in press. Evaluating neutralizing antibodies against HIV, SIV
and SHIV in a luciferase reporter gene assay. In: Coligan, J.E., Kruisbeek,
A.M., Margulies, D.H., Shevach, E.M., Strober, W., Coico, R. (Eds.).
Current Protocols in Immunology. John Wiley and Sons.
Mouland, A.J., Mercier, J., Luo, M., Bernier, L., DesGroseillers, L., Cohen,
E.A., 2000. The double-stranded RNA-binding protein Staufen is
incorporated in human immunodeficiency virus type 1: evidence for a
role in genomic RNA encapsidation. J. Virol. 74 (12), 5441–5451.
Murthy, K.K., Cobb, E.K., Rouse, S.R., McClure, H.M., Payne, J.S., Salas,M.T., Michalek, G.R., 1998. Active and passive immunization against
HIV type 1 infection in chimpanzees. AIDS Res. Hum. Retrovir. 14
(Suppl. 3), S271–S276.
Pancera, M., Lebowitz, J., Schon, A., Zhu, P., Freire, E., Kwong, P.D., Roux,
K.H., Sodroski, J., Wyatt, R., 2005. Soluble mimetics of human
immunodeficiency virus type 1 viral spikes produced by replacement of
the native trimerization domain with a heterologous trimerization motif:
characterization and ligand binding analysis. J. Virol. 79 (15), 9954–9969.
Pancera, M., Wyatt, R., 2005. Selective recognition of oligomeric HIV-1
primary isolate envelope glycoproteins by potently neutralizing ligands
requires efficient precursor cleavage. Virology 332 (1), 145–156.
Peng, B., Wang, L.R., Gomez-Roman, V.R., Davis-Warren, A., Montefiori,
D.C., Kalyanaraman, V.S., Venzon, D., Zhao, J., Kan, E., Rowell, T.J.,
Murthy, K.K., Srivastava, I., Barnett, S.W., Robert-Guroff, M., 2005.
Replicating rather than nonreplicating adenovirus–human immunodefi-
ciency virus recombinant vaccines are better at eliciting potent cellular
immunity and priming high-titer antibodies. J. Virol. 79 (16), 10200–10209.
Putney, S.D., Matthews, T.J., Robey, W.G., Lynn, D.L., Robert-Guroff, M.,
Mueller, W.T., Langlois, A.J., Ghrayeb, J., Petteway Jr., S.R., Weinhold,
K.J., et al., 1986. HTLV-III/LAV-neutralizing antibodies to an E. coli-
produced fragment of the virus envelope. Science 234 (4782), 1392–1395.
Rao, M., Matyas, G.R., Vancott, T.C., Birx, D.L., Alving, C.R., 2004.
Immunostimulatory CpG motifs induce CTL responses to HIV type I
oligomeric gp140 envelope protein. Immunol. Cell. Biol. 82 (5), 523–530.
Reading, S.A., Heap, C.J., Dimmock, N.J., 2003. A novel monoclonal antibody
specific to the C-terminal tail of the gp41 envelope transmembrane protein
of human immunodeficiency virus type 1 that preferentially neutralizes virus
after it has attached to the target cell and inhibits the production of infectious
progeny. Virology 315 (2), 362–372.
Sanders, R.W., Vesanen, M., Schuelke, N., Master, A., Schiffner, L.,
Kalyanaraman, R., Paluch, M., Berkhout, B., Maddon, P.J., Olson, W.C.,
Lu, M., Moore, J.P., 2002. Stabilization of the soluble, cleaved, trimeric
form of the envelope glycoprotein complex of human immunodeficiency
virus type 1. J. Virol. 76 (17), 8875–8889.
Sauter, S.L., Rahman, A., Muralidhar, G., 2005. Non-replicating viral vector-
based AIDS vaccines: interplay between viral vectors and the immune
system. Curr. HIV Res. 3 (2), 157–181.
Schulke, N., Vesanen, M.S., Sanders, R.W., Zhu, P., Lu, M., Anselma, D.J.,
Villa, A.R., Parren, P.W., Binley, J.M., Roux, K.H., Maddon, P.J., Moore,
J.P., Olson, W.C., 2002. Oligomeric and conformational properties of a
proteolytically mature, disulfide-stabilized human immunodeficiency virus
type 1 gp140 envelope glycoprotein. J. Virol. 76 (15), 7760–7776.
Shibata, R., Igarashi, T., Haigwood, N., Buckler-White, A., Ogert, R., Ross, W.,
Willey, R., Cho, M.W., Martin, M.A., 1999. Neutralizing antibody directed
against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV
chimeric virus infections of macaque monkeys. Nat. Med. 5 (2), 204–210.
Si, Z., Phan, N., Kiprilov, E., Sodroski, J., 2003. Effects of HIV type 1 envelope
glycoprotein proteolytic processing on antigenicity. AIDS Res. Hum.
Retrovir. 19 (3), 217–226.
Slobod, K.S., Coleclough, C., Bonsignori, M., Brown, S.A., Zhan, X., Surman,
S., Zirkel, A., Jones, B.G., Sealy, R.E., Stambas, J., Brown, B., Lockey,
T.D., Freiden, P.J., Doherty, P.C., Blanchard, J.L., Martin, L.N., Hurwitz,
J.L., 2005. HIV vaccine rationale, design and testing. Curr. HIV Res. 3
(2), 107–112.
Sminia, T., Draal, G., 1999. Nasal-associated lymphoid tissue. In: Ogra, P.L.,
Lamm,M.E., Bienenstock, J., Mestecky, J., Stober, W., McGhee, J.R. (Eds.),
Mucosal Immunology, vol. 2. Academic Press, London, pp. 357–364.
Smith, J., Amara, R., McClure, H., Patel, M., S, S., Yi, H., Chennareddi, L.,
Herndon, J., Butera, S., Heneine, W., Ellenberger, D., B, P., Earl, P., Wyatt,
L., Moss, B., Robinson, H., 2003. Multiprotein HIV-1 clade B DNA/MVA
vaccine: construction, safety, and immunogenicity. AIDS Res. Hum.
Retrovir. 20, 654–665.
Smith, J.M., Amara, R.R., Campbell, D., Xu, Y., Patel, M., Sharma, S., Butera,
S.T., Ellenberger, D.L., Yi, H., Chennareddi, L., Herndon, J.G., Wyatt, L.S.,
Montefiori, D., Moss, B., McClure, H.M., Robinson, H.L., 2004. DNA/
MVA vaccine for HIV type 1: effects of codon-optimization and the
expression of aggregates or virus-like particles on the immunogenicity of the
DNA prime. AIDS Res. Hum. Retrovir. 20 (12), 1335–1347.
346 S.P. McBurney et al. / Virology 358 (2007) 334–346Spearman, P., 2003. HIV vaccine development: lessons from the past and
promise for the future. Curr. HIV Res. 1 (1), 101–120.
Spenlehauer, C., Saragosti, S., Fleury, H.J., Kirn, A., Aubertin, A.M., Moog, C.,
1998. Study of the V3 loop as a target epitope for antibodies involved in the
neutralization of primary isolates versus T-cell-line-adapted strains of human
immunodeficiency virus type 1. J. Virol. 72 (12), 9855–9864.
Srivastava, I.K., Stamatatos, L., Legg, H., Kan, E., Fong, A., Coates, S.R.,
Leung, L., Wininger, M., Donnelly, J.J., Ulmer, J.B., Barnett, S.W., 2002.
Purification and characterization of oligomeric envelope glycoprotein from a
primary R5 subtype B human immunodeficiency virus. J. Virol. 76 (6),
2835–2847.
Stamatatos, L., Cheng-Mayer, C., 1995. Structural modulations of the envelope
gp120 glycoprotein of human immunodeficiency virus type 1 upon
oligomerization and differential V3 loop epitope exposure of isolates
displaying distinct tropism upon virion-soluble receptor binding. J. Virol. 69
(10), 6191–6198.
Tan, K., Liu, J., Wang, J., Shen, S., Lu, M., 1997. Atomic structure of a
thermostable subdomain of HIV-1 gp41. Proc. Natl. Acad. Sci. U.S.A. 94
(23), 12303–12308.
Tang, S., Murakami, T., Cheng, N., Steven, A.C., Freed, E.O., Levin, J.G., 2003.
Human immunodeficiency virus type 1 N-terminal capsid mutants contain-
ing cores with abnormally high levels of capsid protein and virtually no
reverse transcriptase. J. Virol. 77 (23), 12592–12602.
Tilney, N.L., 1971. Patterns of lymphatic drainage in the adult laboratory rat.
J. Anat. 109 (Pt. 3), 369–383.
Tochikubo, K., Isaka, M., Yasuda, Y., Kozuka, S., Matano, K., Miura, Y.,
Taniguchi, T., 1998. Recombinant cholera toxin B subunit acts as an
adjuvant for the mucosal and systemic responses of mice to mucosally co-
administered bovine serum albumin. Vaccine 16 (2–3), 150–155.
Trkola, A., Purtscher, M., Muster, T., Ballaun, C., Buchacher, A., Sullivan, N.,
Srinivasan, K., Sodroski, J., Moore, J.P., Katinger, H., 1996. Human
monoclonal antibody 2G12 defines a distinctive neutralization epitope on
the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol.
70 (2), 1100–1108.
VanCott, T.C., Mascola, J.R., Kaminski, R.W., Kalyanaraman, V., Hallberg,
P.L., Burnett, P.R., Ulrich, J.T., Rechtman, D.J., Birx, D.L., 1997.
Antibodies with specificity to native gp120 and neutralization activity
against primary human immunodeficiency virus type 1 isolates elicited
by immunization with oligomeric gp160. J. Virol. 71 (6), 4319–4330.
Wang, C.T., Lai, H.Y., Li, J.J., 1998. Analysis of minimal humanimmunodeficiency virus type 1 gag coding sequences capable of virus-
like particle assembly and release. J. Virol. 72 (10), 7950–7959.
Wu, H.Y., Nguyen, H.H., Russell, M.W., 1997. Nasal lymphoid tissue
(NALT) as a mucosal immune inductive site. Scand. J. Immunol. 46 (5),
506–513.
Wyatt, R., Kwong, P.D., Desjardins, E., Sweet, R.W., Robinson, J.,
Hendrickson, W.A., Sodroski, J.G., 1998. The antigenic structure of the
HIV gp120 envelope glycoprotein. Nature 393 (6686), 705–711.
Wyatt, L.S., Earl, P.L., Liu, J.Y., Smith, J.M., Montefiori, D.C., Robinson, H.L.,
Moss, B., 2004. Multiprotein HIV type 1 clade B DNA and MVA vaccines:
construction, expression, and immunogenicity in rodents of the MVA
component. AIDS Res. Hum. Retrovir. 20 (6), 645–653.
Wyatt, R., Sodroski, J., 1998. The HIV-1 envelope glycoproteins: fusogens,
antigens, and immunogens. Science 280 (5371), 1884–1888.
Yang, X., Farzan, M., Wyatt, R., Sodroski, J., 2000. Characterization of stable,
soluble trimers containing complete ectodomains of human immunodefi-
ciency virus type 1 envelope glycoproteins. J. Virol. 74 (12), 5716–5725.
Yang, X., Wyatt, R., Sodroski, J., 2001. Improved elicitation of neutralizing
antibodies against primary human immunodeficiency viruses by soluble
stabilized envelope glycoprotein trimers. J. Virol. 75 (3), 1165–1171.
Yang, X., Lee, J., Mahony, E.M., Kwong, P.D., Wyatt, R., Sodroski, J., 2002.
Highly stable trimers formed by human immunodeficiency virus type 1
envelope glycoproteins fused with the trimeric motif of T4 bacteriophage
fibritin. J. Virol. 76 (9), 4634–4642.
York, J., Follis, K.E., Trahey, M., Nyambi, P.N., Zolla-Pazner, S., Nunberg, J.H.,
2001. Antibody binding and neutralization of primary and T-cell line-
adapted isolates of human immunodeficiency virus type 1. J. Virol. 75 (6),
2741–2752.
Young, K.R., Ross, T.M., 2003. Particle-based vaccines for HIV-1 infection.
Curr. Drug Targets Infect. Disord. 3 (2), 151–169.
Young, K., Ross, T.M., 2005. Elicitation of immunity to HIV-1 gag is
determined by Gag structure. AIDS Res. Hum. Retrovir.
Young, K.R., Smith, J.M., Ross, T.M., 2004. Characterization of a DNAvaccine
expressing a human immunodeficiency virus-like particle. Virology 327 (2),
262–272.
Zhang, C.W., Chishti, Y., Hussey, R.E., Reinherz, E.L., 2001. Expression,
purification, and characterization of recombinant HIV gp140. The gp41
ectodomain of HIV or simian immunodeficiency virus is sufficient to
maintain the retroviral envelope glycoprotein as a trimer. J. Biol. Chem. 276
(43), 39577–39585.
